(CNN) -- The second-to-last time EJ Levy was at Disney World, she used a scooter to navigate the enormous park. Her legs were weak and she suffered from foot drop caused by multiple sclerosis. That was 4½ years ago. On her most recent trip, a few months ago, Levy walked the entire time, thanks in part to a drug approved by the FDA on Friday. The FDA says the drug, Ampyra (generic name dalfampridine, formerly known as fampridine), is the first MS therapy that is taken orally and the first of its kind to receive FDA approval. It is designed help people with any type of MS improve their walking speed.FDA approves Ampyra, the first MS drug of its kind to improve walking speedAmpyra is appropriate for all types of MS, although it may not help everyoneFurther studies are needed to see if Ampyra helps with other neurological functions
Symptoms of _ include extreme fatigue, difficulty walking, problems with memory and heat sensitivity. Two phase III clinical trials of _ showed 35 and 43 percent of patients experienced, on average, a consistent improvement in their walking speed, increasing it by about 25 percent.